Acorda Therapeutics, Inc.
Acorda Therapeutics develops therapies for neurological disorders. The company markets Ampyra for multiple sclerosis and Inbrija for Parkinsons disease. It also markets Ampyra as Fampyra globally. The product pipeline includes Cimaglermin alfa, in Phase 1 trials for neurological injury and heart function. The company has a collaboration with Biogen for Ampyra development. Acorda was incorporated in 1995 and is headquartered in Pearl River, New York.
Overview
Strengths
- Price to book ratio (0.00) is lower than the sector mean (733.70).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data